Overview

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-20
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, multi-center, single-arm clinical trial
Phase:
PHASE2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborator:
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.